Why the study?
Guidelines recommend DES over DCB for ISR based on trials lacking intravascular imaging, but OCT tissue morphology patterns may influence treatment outcomes.
Does OCT-defined ISR tissue morphology affect treatment outcomes with drug-eluting stents versus drug-coated balloons in patients with in-stent restenosis?
Does OCT-defined ISR tissue morphology affect treatment outcomes with drug-eluting stents versus drug-coated balloons in patients with in-stent restenosis?
Answers are grounded in this paper and cite their sources.
The ISAR-DESIRE 5 trial will evaluate whether OCT-defined tissue morphology can guide the choice between drug-eluting stents and drug-coated balloons for treating in-stent restenosis.
In-stent restenosis (ISR) is the leading cause of revascularization failure, occurring in up to 10% of patients within 10 years after drug-eluting stent (DES) implantation, and is associated with increased mortality and rehospitalization. Guideline-writing authorities recommend DES over drug-coated balloons (DCB) for ISR treatment. However, this indication is mainly based on trials that did not incorporate intravascular imaging. Recent findings suggest that optical coherence tomography (OCT) patterns in ISR may influence treatment outcomes. The ISAR-DESIRE 5 trial is a randomized study to evaluate whether OCT-defined ISR tissue morphology affects treatment with DES versus DCB. 376 patients with ISR will be stratified by OCT pattern (homogeneous vs. non-homogeneous) and randomized 1:1 to DES or DCB. The trial is powered to detect an interaction between OCT pattern and treatment modality on the 24-month incidence of major adverse cardiac events and represents a step toward establishing a more individualized approach to ISR management. Trial registration (ClinicalTrials.gov): NCT05544864. Graphical Abstract ISAR-DESIRE 5 Trial design overview. After classification of the predominant OCT restenotic pattern at the site of the MLA as either homogeneous or non-homogeneous, patients will undergo 1:1 randomization to receive either a DES or a DCB, using a stratified randomization approach. This unique design ensures balanced allocation of treatment modalities (DES or DCB) across the two OCT-defined restenotic patterns.
No takes yet. Share an insight, caveat, or question.
Simonetti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: